Cancer pathology

Mountford CE, Doran S, Lean CL, Russell P. Cancer pathology in the year 2000. Biophys Chem 1997 68( 1—3) 127-135. 

For more detailed information about cancer pathology readers are referred to De Vita et al. [7]. 

Viens P, Penault-Llorca F, Jacquemier J, et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer pathologic response and outcome. Bone Marrow Transplant 1998 21 249-254. 

With increasing interest in undertaking animal experimental and human clinical and intervention studies to evaluate the role of lycopene in cancer prevention, it is important that well-established molecular and clinical markers of cancer be used in these studies. In general, the main clinical end points used in animal and human experiments are the tumor burden and volume and survival rates. Now that our understanding of cancer pathology has advanced, several molecular events are beginning to be recognized and used in research to evaluate the outcomes from intervention studies. A brief overview of some of the more important molecular markers of cancer that can and should be used in future studies is presented in this section. 

Jass JR, Familial colorectal cancer pathology and molecular characteristics. Lancet Oncology 2000 1 220-6. 

Schalken JA, Bergh A, Bono A, et al. Molecular prostate cancer pathology current issues and achievements. Scand J Urol Nephrol. 2005 (Suppl)(216) 82. 

Wolf, G., Hildenbrand, R., Schwar, C., Grobholz, R., Kaufmann, M., Stutte, H. J., et al. (2000). Polo-like kinase a novel marker of proliferation Correlation with estrogen-receptor expression in human breast cancer. Pathology, Research and Practice, 196, 753-759. 

Homburger, R Les rapports entre tabac et cancer Pathologic experimentale [The relationship between tobacco and cancer Experimental pathology] Med. Hyg. (Switz.) 23 (1965) 179-181. 

L.B. Woolner, R.S. Fontana, D.A. Cortese (1984). Roentgenographically occult lung cancer Pathologic findings and frequency of multicentricity during a 10-year period. Mayo Clin. Proc., 59, 453—466. 

Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanism in cancer pathology and therapeutic implications. Am J Pathol. 2007 170 1-15. 

Veltri, R.W., Chaudhari, M., Miller, M.C., Poole, E.C., O Dowd, G.X and Partin, A.W. (2002) Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage. Clinical Chemistry, 48 (10), 1828-34. 

There are a number of different cancer pathologies and tumor types. 

---